PeptideDB

PTD-p65-P1 Peptide

CAS: F: C168H275N57O44S W: 3829.50

PTD-p65-P1 Peptide is a potent, selective nuclear transcription factor NF-κB inhibitor and derives from the p65 su
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity PTD-p65-P1 Peptide is a potent, selective nuclear transcription factor NF-κB inhibitor and derives from the p65 subunit of NF-κB amino acid residues 271-282, which selectively inhibits NF-κB activation induced by various inflammatory stimulation, down-regulate NF-κB-mediated gene expression and up-regulate apoptosis[1][2].
Target NF-kappaB
Invitro PTD-p65-P1 Peptide (10-150 μM; 0-60 min; KBM-5 cells) inhibits TNF-induced NF-κB activation in a dose-dependent manner and suppresses TNF-induced NF-κB activation by 25% at 100 μM and completely at 150 μM[1].PTD-p65-P1 Peptide (150 μM; 0-60 min; KBM-5 cells) inhibits cytoplasmic p65 phosphorylation and nuclear translocation[1].PTD-p65-P1 Peptide (100 μM; 16 h; KBM-5 cells) potentiates the TNF-induced apoptosis from 4 to 45%[1].PTD-p65-P1 Peptide (150 μM; A 293 cells) inhibits NF-κB-dependent reporter gene expression induced by TNF[1].PTD-p65-P1 Peptide (150 μM; 12-24 h; SP-53 cells ) inhibits the cell proliferation[2]. Western Blot Analysis[1] Cell Line:
Name PTD-p65-P1 Peptide
Shortening DRQIKIWFQNRRMKWKKQLRRPSDRELSE
Formula C168H275N57O44S
Molar Mass 3829.50
Transport Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Reference [1]. Takada Y, et, al. Identification of a p65 peptide that selectively inhibits NF-kappa B activation induced by various inflammatory stimuli and its role in down-regulation of NF-kappaB-mediated gene expression and up-regulation of apoptosis. J Biol Chem. 20 [2]. Shishodia S, et, al. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol. 2005 Sep 1;70(5):700-13.